A topical fixed-dose combination antifungal and corticosteroid. Sertaconazole is a broad-spectrum imidazole antifungal with anti-inflammatory and antipruritic properties. Beclometasone dipropionate is a potent, medium-potency group III topical corticosteroid. The combination is primarily indicated for the treatment of fungal skin infections complicated by inflammation, pruritus, and eczematization, commonly seen in the Indian tropical climate.
Adult: Apply a thin film to the affected and immediately surrounding area twice daily (morning and evening). Gently massage until absorbed.
Note: 1. Wash and dry the affected area thoroughly. 2. Take a small amount of cream on clean fingertip. 3. Apply a thin layer to cover the lesion and about 1-2 cm of surrounding normal skin. 4. Gently rub in until the cream disappears. 5. Wash hands after application unless hands are being treated. 6. Avoid occlusive dressings unless specifically directed by a physician. 7. Do not use for longer than prescribed.
Sertaconazole exerts a dual fungistatic and fungicidal effect by inhibiting ergosterol biosynthesis in the fungal cell membrane via inhibition of lanosterol 14α-demethylase (CYP51). This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function. It also inhibits neutrophil chemotaxis, providing anti-inflammatory action. Beclometasone dipropionate is a prodrug activated to 17-BMP, which binds to glucocorticoid receptors, modulating gene transcription. This leads to synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, leukotrienes, prostaglandins), resulting in vasoconstriction, reduced edema, and immunosuppression.
Pregnancy: Category C (US FDA). Animal studies show teratogenicity with corticosteroids. No adequate, well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Avoid large areas, prolonged use, or occlusive dressings. Prefer safer alternatives (e.g., topical nystatin, clotrimazole) for simple infections.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids (e.g., Clobetasol, Mometasone) | Additive risk of local and systemic adverse effects (atrophy, HPA suppression). | Major |
| Systemic Corticosteroids (e.g., Prednisolone, Dexamethasone) | Increased risk of hypercorticism and adrenal suppression. | Major |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | Potential increased risk of skin infection; concurrent use not recommended. | Moderate |
| Strong CYP3A4 Inhibitors (Systemic - e.g., Ketoconazole, Itraconazole, Ritonavir) | May theoretically inhibit metabolism of systemically absorbed beclometasone, increasing corticosteroid side effects. Risk is low with topical use on limited areas. | Theoretical/Minor |
Same composition (Sertaconazole (2% w/w) + Beclometasone (0.025% w/w)), different brands: